{"schema_version":"secwatch.filing_event.v1","accession":"0001563665-22-000019","form_type":"8-K","ticker":"HRGN","cik":"0001563665","company_name":"Harvard Apparatus Regenerative Technology, Inc.","filed_at":"2022-12-23T23:59:59+00:00","discovered_at":"2026-05-14T18:03:51.174512+00:00","generated_at":"2026-06-20T23:20:56.594344+00:00","sec_items":["8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.4,"calibrated_materiality_score":0.4,"confidence":"high","headline":"Biostage Announces Publication Showing Rapid Esophageal Regeneration in Pigs","bullets":["Publication in Journal of Immunology and Regenerative Medicine describes regeneration after Biostage Esophageal Implant in nine pigs with full circumferential replacement.","All animals regenerated a continuous biological conduit by 28 days; some as early as 14 days.","Regeneration time compares favorably with FDA-approved clinical trial primary endpoint of 90 days.","Biostage expects to initiate patient recruitment in first clinical trial in early 2023.","Study also quantified epithelialization and fate of adipose-derived mesenchymal stromal cells."],"urls":{"canonical":"https://secwatch.observer/filing/0001563665-22-000019","json":"https://secwatch.observer/filing/0001563665-22-000019.json","markdown":"https://secwatch.observer/filing/0001563665-22-000019.md","text":"https://secwatch.observer/filing/0001563665-22-000019.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1563665/000156366522000019/0001563665-22-000019-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1563665/000156366522000019/tmb-20221223x8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-20T23:20:56.594344+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}